Cargando…

Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study

OBJECTIVE: The aim of this retrospective study was to evaluate the efficacy and prognostic factors of bortezomib and dexamethasone (BD) chemotherapy regimen in the treatment of newly diagnosed multiple myeloma (MM) patients in our hospital. METHODS: A total of 47 newly diagnosed MM patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Runzhe, Zhang, Xiaoping, Gao, Chong, Luan, Chengxin, Wang, Yujie, Chen, Baoan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576706/ https://www.ncbi.nlm.nih.gov/pubmed/28883741 http://dx.doi.org/10.2147/CMAR.S144405

Ejemplares similares

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis
por: Chen, Runzhe, et al.
Publicado: (2017)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma
por: Chen, Runzhe, et al.
Publicado: (2017)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
por: Yokoyama, Akihiro, et al.
Publicado: (2022)

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
por: Ashrafi, Farzaneh, et al.
Publicado: (2020)

Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
por: Narsipur, Nihal, et al.
Publicado: (2021)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
por: Xu, Peipei, et al.
Publicado: (2019)

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review
por: McCaughan, Georgia J., et al.
Publicado: (2022)

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2023)

P909: RENAL RESPONSE OF POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT
por: Jian, Y., et al.
Publicado: (2022)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma
por: Becker, P S, et al.
Publicado: (2016)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

P909: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE CHEMOTHERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: POMACE PHASE II STUDY
por: Saj, Fen, et al.
Publicado: (2023)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
por: Crusoe, Edvan De Queiroz, et al.
Publicado: (2020)

PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA
por: Nameera, Rahmathullah Sulaimankutty, et al.
Publicado: (2023)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
por: Liu, Xiao, et al.
Publicado: (2022)

Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients
por: Zhou, Qiaolin, et al.
Publicado: (2022)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
por: Sborov, Douglas W., et al.
Publicado: (2022)

Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study
por: Saj, Fen, et al.
Publicado: (2023)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
por: Kropff, Martin, et al.
Publicado: (2009)

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
por: Ocio, Enrique M., et al.
Publicado: (2023)

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
por: Wang, Hua, et al.
Publicado: (2016)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial
por: Shah, J J, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_uslsb2cfq5pan5cr4aq71nf8aq